Joint Formulary & PAD

Leuprorelin acetate - Endometriosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Injection
Associated Icons :
SPC
Restrictions / Comments :
Important

The specialist team should initiate treatment and administer the 1st injection prior to transfer of care.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Leuprorelin acetate
Indication :
Endometriosis
Group Name :
Keywords :
Injection
Brand Names Include :
Prostap 3 DCS, Prostap SR DCS
Important Information :
Latest Additions Date From :
13 Nov 2025
Latest Additions Date To :
13 Dec 2025
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a traffic light status for patients being treated for Endometriosis

Leuprorelin for this indication will be considered BLUE (with specialist team initiation). The specialist team will prescribe and administer the 1st injection prior to transfer of care to primary care colleagues.

A Locally Commissioned Service (LCS) is available.

Other Indications

Below are listed other indications that Leuprorelin acetate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Endometriosis.